OPKO Health, Inc. (NASDAQ:OPK) Files An 8-K Regulation FD Disclosure
ITEM7.01.
| Regulation FD Disclosure. |
As previously disclosed, on January11, 2017 at 9:00 AM (PT), OPKO
Health, Inc. (the Company) will present at the J.P. Morgan 35th
Annual Healthcare Conference. The presentation will be webcast on
the Investor Relations page of the Companys corporate website at
www.opko.com. A copy of the Companys presentation slides
is furnished as Exhibit 99.1 to this Current Report on Form 8-K
and will also be available the day of the presentation on the
OPKO website at www.opko.com under Investor Relations.
The information contained in Item 7.01 to this Current Report on
Form 8-K and Exhibit 99.1 attached hereto shall not be deemed
filed for purposes of Section18 of the Exchange Act, or otherwise
subject to the liabilities of that section, nor shall it be
deemed incorporated by reference in any filing by the Company
under the Act.
ITEM9.01. |
Financial Statements and Exhibits. |
(d) |
Exhibits |
|
|
|
|
| 99.1 |
The Companys J.P. Morgan 35th Annual Healthcare Conference presentation slides |
About OPKO Health, Inc. (NASDAQ:OPK)
OPKO Health, Inc. (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations. The Company’s diagnostics business includes Bio-Reference Laboratories (Bio-Reference), which is a clinical laboratory with a genetic testing business, including the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. Its pharmaceutical business includes OPKO Biologics, which features hGH-CTP, a once-weekly human growth hormone injection (in Phase III and partnered with Pfizer), and a longer acting Factor VIIa drug for hemophilia (Phase IIa). In addition to its pharmaceutical and diagnostic development programs, it owns pharmaceutical platforms in Ireland, Chile, Spain and Mexico. OPKO Health, Inc. (NASDAQ:OPK) Recent Trading Information
OPKO Health, Inc. (NASDAQ:OPK) closed its last trading session up +0.06 at 9.37 with 3,520,410 shares trading hands.
